IL115420A0
(en)
|
1994-09-26 |
1995-12-31 |
Zeneca Ltd |
Aminoheterocyclic derivatives
|
GB9516709D0
(en)
*
|
1995-08-15 |
1995-10-18 |
Zeneca Ltd |
Medicament
|
US6083949A
(en)
*
|
1995-10-06 |
2000-07-04 |
Merck & Co., Inc. |
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
|
GB9602166D0
(en)
|
1996-02-02 |
1996-04-03 |
Zeneca Ltd |
Aminoheterocyclic derivatives
|
EP0880501A1
(en)
|
1996-02-02 |
1998-12-02 |
Zeneca Limited |
Heterocyclic compounds useful as pharmaceutical agents
|
US5883105A
(en)
*
|
1996-04-03 |
1999-03-16 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5859012A
(en)
*
|
1996-04-03 |
1999-01-12 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5852010A
(en)
*
|
1996-04-03 |
1998-12-22 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5939557A
(en)
*
|
1996-04-03 |
1999-08-17 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5885995A
(en)
*
|
1996-04-03 |
1999-03-23 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5965578A
(en)
*
|
1996-04-03 |
1999-10-12 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5919785A
(en)
*
|
1996-04-03 |
1999-07-06 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
JP2000507579A
(en)
*
|
1996-04-03 |
2000-06-20 |
メルク エンド カンパニー インコーポレーテッド |
Farnesyl-protein transferase inhibitor
|
US5922883A
(en)
*
|
1996-04-03 |
1999-07-13 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
EP0891353A4
(en)
*
|
1996-04-03 |
2001-08-08 |
Merck & Co Inc |
Inhibitors of farnesyl-protein transferase
|
US5780488A
(en)
*
|
1996-04-03 |
1998-07-14 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
AU707347B2
(en)
*
|
1996-04-03 |
1999-07-08 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6063930A
(en)
*
|
1996-04-03 |
2000-05-16 |
Merck & Co., Inc. |
Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
|
US5925651A
(en)
*
|
1996-04-03 |
1999-07-20 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5891889A
(en)
*
|
1996-04-03 |
1999-04-06 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
EP0944388A4
(en)
*
|
1996-04-03 |
2001-08-16 |
Merck & Co Inc |
Inhibitors of farnesyl-protein transferase
|
US6001835A
(en)
*
|
1996-04-03 |
1999-12-14 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5780492A
(en)
*
|
1996-04-03 |
1998-07-14 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6080870A
(en)
*
|
1996-04-03 |
2000-06-27 |
Merck & Co., Inc. |
Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
|
WO1997036583A1
(en)
*
|
1996-04-03 |
1997-10-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5869682A
(en)
*
|
1996-04-03 |
1999-02-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5874452A
(en)
*
|
1996-04-03 |
1999-02-23 |
Merck & Co., Inc. |
Biheteroaryl inhibitors of farnesyl-protein transferase
|
CA2250232A1
(en)
*
|
1996-04-03 |
1997-10-09 |
Allen I. Oliff |
A method of treating cancer
|
JP2000507589A
(en)
*
|
1996-04-03 |
2000-06-20 |
メルク エンド カンパニー インコーポレーテッド |
Farnesyl-protein transferase inhibitor
|
PL331599A1
(en)
*
|
1996-08-14 |
1999-08-02 |
Zeneca Ltd |
Substituted derivatives of pyrimidine and their pharmaceutical application
|
UA56197C2
(en)
|
1996-11-08 |
2003-05-15 |
Зенека Лімітед |
Heterocyclic derivatives
|
AU6013998A
(en)
*
|
1996-12-30 |
1998-07-31 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
AU5999798A
(en)
|
1997-02-13 |
1998-09-08 |
Zeneca Limited |
Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
|
JP2001511798A
(en)
|
1997-02-13 |
2001-08-14 |
ゼネカ・リミテッド |
Heterocyclic compounds useful as oxide-squalene cyclase inhibitors
|
US5972942A
(en)
*
|
1997-03-27 |
1999-10-26 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6060038A
(en)
*
|
1997-05-15 |
2000-05-09 |
Merck & Co., Inc. |
Radiolabeled farnesyl-protein transferase inhibitors
|
AUPO735997A0
(en)
|
1997-06-17 |
1997-07-10 |
Fujisawa Pharmaceutical Co., Ltd. |
Piperazine derivatives
|
GB9715895D0
(en)
|
1997-07-29 |
1997-10-01 |
Zeneca Ltd |
Heterocyclic compounds
|
AU8921398A
(en)
*
|
1997-08-27 |
1999-03-16 |
Merck & Co., Inc. |
A method of treating cancer
|
US6387903B1
(en)
|
1997-08-27 |
2002-05-14 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US6103487A
(en)
*
|
1997-08-27 |
2000-08-15 |
Merck & Co., Inc. |
Method of treating cancer
|
FR2774985A1
(en)
*
|
1998-02-13 |
1999-08-20 |
Rhone Poulenc Rorer Sa |
New naphthyl carbonyl or sulfonyl oxopiperazine farnesyl transferase inhibitors, used as antiproliferative agents, e.g. for treating cancer
|
WO1999041242A1
(en)
*
|
1998-02-13 |
1999-08-19 |
Rhone-Poulenc Rorer S.A. |
Di-substituted naphthyl derivatives, preparation thereof, pharmaceutical compositions containing them
|
AU5086499A
(en)
*
|
1998-07-01 |
2000-01-24 |
Merck & Co., Inc. |
Process for making farnesyl-protein transferase inhibitors
|
GB9902989D0
(en)
|
1999-02-11 |
1999-03-31 |
Zeneca Ltd |
Heterocyclic derivatives
|
US6358956B1
(en)
*
|
1999-03-03 |
2002-03-19 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
EP1165013A4
(en)
*
|
1999-03-03 |
2002-08-07 |
Merck & Co Inc |
Inhibitors of prenyl-protein transferase
|
CA2362494A1
(en)
*
|
1999-03-03 |
2000-09-08 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
AU3386600A
(en)
*
|
1999-03-03 |
2000-09-21 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US6211182B1
(en)
*
|
1999-03-08 |
2001-04-03 |
Schering Corporation |
Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
|
US6458935B1
(en)
|
1999-06-23 |
2002-10-01 |
Merck & Co., Inc. |
Radiolabeled farnesyl-protein transferase inhibitors
|
FR2819509B1
(en)
|
2001-01-18 |
2004-04-16 |
Servier Lab |
NOVEL CYCLOHEPTENE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
FR2819512B1
(en)
*
|
2001-01-18 |
2003-02-21 |
Servier Lab |
NOVEL CYCLO [D] AZEPANE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
FR2819510B1
(en)
*
|
2001-01-18 |
2003-10-31 |
Servier Lab |
NOVEL CYCLO [C] AZEPANE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
|
ATE550019T1
(en)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
CIS-4-Ä(4-CHLOROPHENYL)SULFONYLÜ-4-(2,5-DIFLUOROPHENYL)CYCLOHEXANEPROPANE ACID FOR THE TREATMENT OF CANCER
|
DE602006016313D1
(en)
|
2005-09-16 |
2010-09-30 |
Arrow Therapeutics Ltd |
BIPHENYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS C
|
EP2426129B1
(en)
|
2005-12-13 |
2016-11-02 |
Incyte Holdings Corporation |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
CA2664113C
(en)
|
2006-09-22 |
2013-05-28 |
Merck & Co., Inc. |
Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
MX2009006631A
(en)
*
|
2006-12-18 |
2009-06-30 |
Novartis Ag |
Organic compounds.
|
EP2805945B1
(en)
|
2007-01-10 |
2019-04-03 |
MSD Italia S.r.l. |
Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
|
AU2008221263B2
(en)
|
2007-03-01 |
2012-02-23 |
Novartis Ag |
Pim kinase inhibitors and methods of their use
|
AU2008254425A1
(en)
|
2007-05-21 |
2008-11-27 |
Novartis Ag |
CSF-1R inhibitors, compositions, and methods of use
|
PT3070090T
(en)
|
2007-06-13 |
2019-03-20 |
Incyte Holdings Corp |
Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
|
JP5501227B2
(en)
|
2007-06-27 |
2014-05-21 |
メルク・シャープ・アンド・ドーム・コーポレーション |
4-Carboxybenzylamino derivatives as histone deacetylase inhibitors
|
TW200922548A
(en)
|
2007-10-05 |
2009-06-01 |
Acucela Inc |
Alkoxy compounds for disease treatment
|
EP2110374A1
(en)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
|
GB0813144D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
GB0813142D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
WO2010105243A1
(en)
|
2009-03-13 |
2010-09-16 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
JP5756457B2
(en)
|
2009-04-06 |
2015-07-29 |
アジオス ファーマシューティカルズ, インコーポレイテッド |
Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use
|
RS59632B1
(en)
|
2009-05-22 |
2020-01-31 |
Incyte Holdings Corp |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
WO2010135650A1
(en)
|
2009-05-22 |
2010-11-25 |
Incyte Corporation |
N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
|
WO2010144909A1
(en)
|
2009-06-12 |
2010-12-16 |
Novartis Ag |
Fused heterocyclic compounds and their uses
|
RU2561132C2
(en)
|
2009-06-29 |
2015-08-20 |
Аджиос Фармасьютикалз, Инк. |
Derivatives of chinolinesulphonamides and their application for modulation of pkm2 activity
|
EP4000610A1
(en)
|
2009-07-02 |
2022-05-25 |
Acucela Inc. |
Pharmacology of visual cycle modulators
|
US9249145B2
(en)
|
2009-09-01 |
2016-02-02 |
Incyte Holdings Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
JP5099731B1
(en)
|
2009-10-14 |
2012-12-19 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Substituted piperidines that increase p53 activity and uses thereof
|
EP3561077B1
(en)
|
2009-10-21 |
2022-12-21 |
Les Laboratoires Servier |
Methods for cell-proliferation-related disorders
|
WO2011090738A2
(en)
|
2009-12-29 |
2011-07-28 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
KR102354472B1
(en)
|
2010-03-10 |
2022-01-21 |
인사이트 홀딩스 코포레이션 |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
EA201290919A1
(en)
|
2010-03-16 |
2013-03-29 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
INDASOLIC COMPOUNDS AND THEIR APPLICATION
|
HUE029035T2
(en)
|
2010-05-21 |
2017-01-30 |
Incyte Holdings Corp |
Topical formulation for a jak inhibitor
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
EP3330377A1
(en)
|
2010-08-02 |
2018-06-06 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
EP3587574B1
(en)
|
2010-08-17 |
2022-03-16 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
WO2012027236A1
(en)
|
2010-08-23 |
2012-03-01 |
Schering Corporation |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
EP3327125B1
(en)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
CA2818545C
(en)
|
2010-11-19 |
2019-04-16 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
|
TW201249845A
(en)
|
2010-11-19 |
2012-12-16 |
Incyte Corp |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
CA2821975A1
(en)
|
2010-12-17 |
2012-06-21 |
Shunqi Yan |
N-(4-(azetidine-1-carbonyl)phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase m2 pkm2 modulators
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
US9328077B2
(en)
|
2010-12-21 |
2016-05-03 |
Agios Pharmaceuticals, Inc |
Bicyclic PKM2 activators
|
TWI549947B
(en)
|
2010-12-29 |
2016-09-21 |
阿吉歐斯製藥公司 |
Therapeutic compounds and compositions
|
CN103732592A
(en)
|
2011-04-21 |
2014-04-16 |
默沙东公司 |
Insulin-like growth factor-1 receptor inhibitors
|
EP2704721B1
(en)
|
2011-05-03 |
2018-04-11 |
Agios Pharmaceuticals, Inc. |
Pyruvate kinase activators for use in therapy
|
CN103608016A
(en)
|
2011-05-03 |
2014-02-26 |
安吉奥斯医药品有限公司 |
Pyruvate kinase activators for use in therapy
|
CN102827073A
(en)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
Therapeutically active compositions and application methods thereof
|
CN102827170A
(en)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
Active treatment compositions and use method thereof
|
AR086983A1
(en)
|
2011-06-20 |
2014-02-05 |
Incyte Corp |
DERIVATIVES OF AZETIDINIL FENIL, PIRIDIL OR PIRAZINIL CARBOXAMIDA AS JAK INHIBITORS
|
TW201313721A
(en)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
Cyclohexyl azetidine derivatives as JAK inhibitors
|
UA111854C2
(en)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
JP6106685B2
(en)
|
2011-11-17 |
2017-04-05 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
Inhibitors of C-JUN-N-terminal kinase (JNK)
|
US9474779B2
(en)
|
2012-01-19 |
2016-10-25 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compositions and their methods of use
|
WO2013155223A1
(en)
*
|
2012-04-10 |
2013-10-17 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
WO2013165816A2
(en)
|
2012-05-02 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
AR091079A1
(en)
|
2012-05-18 |
2014-12-30 |
Incyte Corp |
DERIVATIVES OF PIRROLOPIRIMIDINA AND PIRROLOPIRIDINA REPLACED WITH PIPERIDINILCICLOBUTILO AS JAK INHIBITORS
|
BR112015006990A2
(en)
|
2012-09-28 |
2017-07-04 |
Merck Sharp & Dohme |
compound, pharmaceutical composition, and use of at least one compound
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
USRE48175E1
(en)
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
CN113384546A
(en)
|
2012-11-15 |
2021-09-14 |
因赛特公司 |
Sustained release dosage forms of ruxolitinib
|
PT2925888T
(en)
|
2012-11-28 |
2017-12-13 |
Merck Sharp & Dohme |
Compositions and methods for treating cancer
|
CA2895504A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
US9540377B2
(en)
|
2013-01-30 |
2017-01-10 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as HDM2 inhibitors
|
EP3985008A1
(en)
|
2013-03-06 |
2022-04-20 |
Incyte Holdings Corporation |
Processes and intermediates for making a jak inhibitor
|
CA2905751A1
(en)
|
2013-03-13 |
2014-10-09 |
Forma Therapeutics, Inc. |
Novel compounds and compositions for inhibition of fasn
|
WO2015003360A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
EP3019480B1
(en)
|
2013-07-11 |
2020-05-06 |
Agios Pharmaceuticals, Inc. |
2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
|
US9579324B2
(en)
|
2013-07-11 |
2017-02-28 |
Agios Pharmaceuticals, Inc |
Therapeutically active compounds and their methods of use
|
WO2015003355A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
US20150031627A1
(en)
|
2013-07-25 |
2015-01-29 |
Agios Pharmaceuticals, Inc |
Therapeutically active compounds and their methods of use
|
RS60469B1
(en)
|
2013-08-07 |
2020-07-31 |
Incyte Corp |
Sustained release dosage forms for a jak1 inhibitor
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
CA2927917C
(en)
|
2013-10-18 |
2022-08-09 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of proliferative diseases
|
US10047070B2
(en)
|
2013-10-18 |
2018-08-14 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
US9968595B2
(en)
|
2014-03-14 |
2018-05-15 |
Agios Pharmaceuticals, Inc. |
Pharmaceutical compositions of therapeutically active compounds
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
US9862688B2
(en)
|
2014-04-23 |
2018-01-09 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
JO3589B1
(en)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
Protein kinase c inhibitors and methods of their use
|
RU2741576C2
(en)
|
2014-10-24 |
2021-01-27 |
Лэндос Байофарма, Инк. |
Medicines based on lantionine synthetase of c-like protein 2
|
EP3236959A4
(en)
|
2014-12-23 |
2018-04-25 |
Dana Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
AU2016243529B2
(en)
|
2015-03-27 |
2021-03-25 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
LT3307271T
(en)
|
2015-06-11 |
2023-10-25 |
Agios Pharmaceuticals, Inc. |
Methods of using pyruvate kinase activators
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
JP7028766B2
(en)
|
2015-09-09 |
2022-03-02 |
ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド |
Inhibitor of cyclin-dependent kinase
|
BR122024000250A2
(en)
|
2015-10-15 |
2024-02-27 |
Les Laboratoires Servier |
USE OF A MUTANT ISOCITRATE 1 (IDH1) DEHYDROGENASE INHIBITOR AND A DNA DEMETHYLATING AGENT
|
DK3362065T3
(en)
|
2015-10-15 |
2024-06-17 |
Servier Lab |
COMBINATION THERAPY INCLUDING IVOSIDENIB, CYTARABINE AND DAUNORUBICIN OR IDARUBICIN FOR TREATMENT OF ACUTE MYELOID LEUKEMIA
|
JOP20190055A1
(en)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
Anti-cd27 antibodies
|
WO2018071283A1
(en)
|
2016-10-12 |
2018-04-19 |
Merck Sharp & Dohme Corp. |
Kdm5 inhibitors
|
CN110650976B
(en)
|
2017-04-13 |
2024-04-19 |
赛罗帕私人有限公司 |
Anti-SIRP alpha antibodies
|
EP4092013A1
(en)
|
2017-06-20 |
2022-11-23 |
Imbria Pharmaceuticals, Inc. |
Compositions and methods for increasing efficiency of cardiac metabolism
|
EP3706742B1
(en)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
TW201924683A
(en)
|
2017-12-08 |
2019-07-01 |
美商英塞特公司 |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
CN112105608B
(en)
|
2018-01-30 |
2023-07-14 |
因赛特公司 |
Process for the preparation of (1- (3-fluoro-2- (trifluoromethyl) isonicotinyl) piperidin-4-one
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
CN110294713B
(en)
*
|
2018-03-22 |
2022-08-02 |
西华大学 |
Preparation method of imidazole methylamine derivative
|
EP3773593B1
(en)
|
2018-03-30 |
2024-05-15 |
Incyte Corporation |
Treatment of hidradenitis suppurativa using jak inhibitors
|
US10980788B2
(en)
|
2018-06-08 |
2021-04-20 |
Agios Pharmaceuticals, Inc. |
Therapy for treating malignancies
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
TWI767148B
(en)
|
2018-10-10 |
2022-06-11 |
美商弗瑪治療公司 |
Inhibiting fatty acid synthase (fasn)
|
US10793554B2
(en)
|
2018-10-29 |
2020-10-06 |
Forma Therapeutics, Inc. |
Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
|
CA3135502C
(en)
|
2019-12-20 |
2024-01-09 |
Josep Bassaganya-Riera |
Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
US11530184B2
(en)
|
2020-06-30 |
2022-12-20 |
Imbria Pharmaceuticals, Inc. |
Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
US11780811B2
(en)
|
2020-06-30 |
2023-10-10 |
Imbria Pharmaceuticals, Inc. |
Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
US11883396B2
(en)
|
2021-05-03 |
2024-01-30 |
Imbria Pharmaceuticals, Inc. |
Methods of treating kidney conditions using modified forms of trimetazidine
|